Clicky

Entrada Therapeutics, Inc.(TRDA)

Description: Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).


Keywords: Medicine Biotechnology Biopharmaceutical Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Genetic Genealogy Myotonic Dystrophy Neuromuscular Disease

Home Page: www.entradatx.com

TRDA Technical Analysis

6 Tide Street
Boston, MA 02210
United States
Phone: 857 520 9158


Officers

Name Title
Mr. Dipal Doshi Pres, CEO & Director
Mr. Nathan J. Dowden Chief Operating Officer
Dr. Natarajan Sethuraman Ph.D. Chief Scientific Officer
Mr. Kory James Wentworth CPA CFO & Treasurer
Dr. Jared Cohen J.D., Ph.D. Gen. Counsel
Ms. Kerry Robert M.S. VP of People
Dr. Nerissa C. Kreher M.B.A., M.D., M.S. Chief Medical Officer
Ms. Karla MacDonald Chief Corp. Affairs Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.568
Price-to-Sales TTM: 0
IPO Date: 2021-10-29
Fiscal Year End: December
Full Time Employees: 124
Back to stocks